Exploiting Multiple Pathways for Best-in-Class Treatment Strategies

Elusive and complex, pervasive and diverse, cancer remains one of the most challenging diseases of our lifetime. Its adaptive nature requires formidable exploration to understand tumor genesis and how treatments can be devised to suppress and kill cancer cells. We strive to be at the forefront of this research, exploiting cancer’s multiple pathways that can be inhibited or modulated, thus making the disease an excellent candidate for combination therapy.

Devising New Strategies To Treat And Defeat Cancer

We are making consistent headway against difficult-to-treat cancers with small molecule therapies that work alone and in combination with treatment regimens to precisely target different and complementary pathways.

About Genitourinary Cancers

Genitourinary cancers are those that affect the urinary tract, bladder, kidneys, ureter, prostate, testicles, penis or adrenal glands — parts of the body involved in reproduction and excretion — and include renal cell carcinoma (RCC) and urothelial carcinoma.1

The American Cancer Society’s 2019 statistics cite kidney cancer as among the top ten most commonly diagnosed forms of cancer among both men and women in the U.S.2 Clear cell RCC is the most common type of kidney cancer in adults.3 If detected in its early stages, the five-year survival rate for RCC is high; for patients with advanced or late-stage metastatic RCC, however, the five-year survival rate is only 12 percent, with no identified cure for the disease.2 Approximately 32,000 patients in the U.S. and 70,000 globally require treatment, and an estimated 15,000 patients in the U.S. each year are in need of a first-line treatment for advanced kidney cancer.4

Urothelial cancers encompass carcinomas of the bladder, ureter and renal pelvis at a ratio of 50:3:1, respectively.5 Bladder cancer occurs mainly in older people, with 90 percent of patients aged 55 or older.6 It is the fourth most common cancer in men and accounts for about five percent of all new cases of cancer in the U.S. each year.2,7 In 2015, an estimated 708,000 people were living with bladder cancer in the U.S.7

About Hepatocellular Carcinoma

Liver cancer is a leading cause of cancer death worldwide, accounting for more than 700,000 deaths and 800,000 new cases each year.8 In the U.S., the incidence of liver cancer has more than tripled since 1980.2 HCC is the most common form of liver cancer, making up about three-fourths of the estimated 42,000 new cases in the U.S. in 2019.2 HCC is the fastest-rising cause of cancer-related death in the U.S.9 Without treatment, patients with advanced HCC usually survive less than 6 months.10

  1. National Cancer Institute Dictionary of Cancer Terms. Genitourinary System. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/genitourinary-system. Accessed April 2019.
  2. American Cancer Society: Cancer Facts & Figures 2019. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf. Accessed April 2019.
  3. Jonasch, E., Gao, J., Rathmell, W., Renal cell carcinoma. BMJ. 2014; 349:g4797.
  4. Decision Resources Report: Renal Cell Carcinoma. October 2014 (internal data on file).
  5. Hurwitz, M. et al. Urothelial and Kidney Cancers. Cancer Management. http://www.cancernetwork.com/cancer-management/urothelial-and-kidney-cancers. Accessed April 2019.
  6. American Cancer Society. Bladder Cancer Key Statistics. https://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-key-statistics. Accessed April 2019.
  7. National Cancer Institute. SEER Stat Fact Sheets: Bladder Cancer. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed April 2019.
  8. International Agency for Research on Cancer. GLOBOCAN 2018. Liver Fact Sheet. Available at: http://gco.iarc.fr/today/data/factsheets/cancers/11-Liver-fact-sheet.pdf. Accessed April 2019.
  9. Mittal S, El-Serag HB. Epidemiology of HCC: Consider the Population. J Clin Gastroenterol. 2013. 47:S2-S6.
  10. Weledji E, Orock G, Ngowe M, NsaghaD. How grim is hepatocellular carcinoma? Ann Med Surg. 2014. 3:71-76.

Patient Stories

Learn more about what motivates us help patients with cancer thrive